Member Info for technick

We shall wait and see Sam, I suspect nowhere but time will tell. My experience says they’ll not have the sensitivity required... Avacta have played a blinder in as much as they’re not making any tests, they’re giving their affimer and letting others take the risk. As I said time will tell

The two big ticket items are going to be RNSs on sales and orders and FDA/WHO. Those will stop the current pattern that plays on incompleteness

Hopefully a rise in share price this week to reflect the coming sales, and another RNS would be welcome on those sales opportunities. I’m thinking a market can of £100m+ is achievable short term

@sam yes I tend to agree, even at £10 in India that would be private labs, a massive market !

Not least for testing within the DOD, no FDA required

Scale of testing for asymptomatic individuals in China is immense

https://www.reuters.com/article/us-health-coronavirus-china-wuhan/chinas-wuhan-says-conducted-1146156-covid-19-tests-on-may-23-idUSKBN2300GG

An asymptomatic person who had the virus have been shown to be qPCR positive and could then self Isolate to prevent infections others

Hi flying, well that is interesting, so as I suspected the test has managed to identify at least one additional positive in the data set which if established to be correct would make it a more sensitive test to the current gold standard. I wonder if we will see any confirmation as more data is optained from commercial use. Exciting stuff.

Sales of their beads, fda, who, point of care

Laser based biosensors... wishful thinking

I agree fuel, in a world where there are many companies basing their product development on wishful thinking I think Genedrive should get a lot of credit in setting the correct level of expectation. Genedrive have in my opinion a reliable and proven platform both for their chemistry in partnership with Cytiva, but also their point of care Genedrive platform. Again I see lots of noise being made by companies that have platforms based on inferior chemistries and a lot of these will fail as they have done previously. By using the gold standard, Genedrive will thrive and have the funds in place to do that.

We should start hearing about sales of their test and also FDA/WHO approvals. This is a world beating test and platform!

Hi Flying thanks for that, the order is odd as sensitivity is always quoted before specificity, that just adds to the confusion, oh well hopefully they’ll correct the order or correct the wording. Good test either way. Hopping sales RNS next week and a better climb in share price based on expected sales.

There was an interesting detail in the reported results on Friday which stated that during evaluations of 180 randomized specimens, the Genedrive 96 SARS-CoV-2 Kit achieved 100 percent sensitivity and 98.2 percent specificity.

What's interesting is that these results were against a lab-based test. The Genedrive called all of the positives as positive hence the 100% sensitivity... but must have called a previously negative test as positive in order for the specificity to also not be 100%. That raises the tantalising possibility that the Genedrive test is more sensitive than the lab based test.

Technically LAMP is a dog of a chemistry and has not been as sensitive as qPCR which is what Genedrive uses and is the gold standard. When available the Genedrive POC platform will provide a better solution to the LAMP based offers which will fail in clinical testing. These companies are using LAMP because the devices are simpler to make, again shows the elegance of the genedrive platform.

Anyone into patents I found this granted patent

https://patents.google.com/patent/US8940524B2/en?oq=US8940524B2

true

The reported scale is 10k per hour so 240k in a 24 hour period or 1,680,000 per week. At £8-10 per test that's your £15m per week. 60% margin is £9m per week...

What’s the feeling about the poor movement today? Seems Peel are sitting on a sell order perhaps? I’m sure all will become clear, what is clear from the opportunity is that there will be a rerate sooner or later. £3 doable imo

@JSB1989

1. It has a long shelf life at room temperature, others need freezers after shipping, an issue for international customers
2. it is pre-dosed, so you just add sample, others need to be mixed. This means more sample can be used making it theoretically more sensitive
3. It is an endpoint test meaning that a number of conventional PCR instruments can be used which then feed a single realtime instrument to read the result. Significant scope to run tests as conventional PCR machines are 100:1+ more prevalent. Reduces capital costs, increases throughput, lowers amortised test cost
4. the chemistry is more tolerant of mutations, other tests will fall over when mutations are present, the Genedrive test won't. This may be important where mutations are present in the regions being tested. Clinical sequence data suggests this could be becoming an issue, the longer it goes on the more of a problem it will be
5. Pricing is good
6. Compatible with the Genedrive POC unit, same test then run in lab and on the road.

Agree it doesn't match the news, so I guess they must be working a sell for a customer?

Out before but it will catch people out because although they have said availability in December, the same bead test that's CE-IVD will be able to be used in Genedrive I'm sure, that means it's not that long before it's available imo. Big news too when it comes.

Frustrating that the market is Luke warm to the CE-IVD and commercial availability. I suspect there's some shenanigans in the background that we don't see - risk removed so good entry point